CFTR and cystic fibrosis: Combined, these data indicate that around 80% of CF patients in European populations carry at least one allele that renders them susceptible to treatment with currently available CFTR potentiators and CFTR correctors (p.F508del, p.G551D, p.S549N and c.3717 + 12191C > T).